How Can AML Patients Get Involved With Clinical Trials?

Published on

Topics include: Clinical Trials , Self-Advocacy and Empowerment , Treatment | General , Treatment and Understanding

Enrollment in clinical trials in the United States is staggeringly low, but sadly this is how new medicines are developed and become available to more patients. Tune in as Leah Szumita, from The Leukemia & Lymphoma Society (LLS), breaks down for us how patients can get involved in clinic trials and what to expect. Leah provides us with great insight as to where patients and their families can find information about clinical trials, speak with a nurse navigator, and questions to ask your doctor. 

This is a Patient Empowerment Network program produced by Patient Power in partnership with The Leukemia & Lymphoma Society (LLS). We thank Celgene Corporation, Daiichi Sankyo, Genentech, Helsinn and Novartis for their support.

View more programs featuring and

Produced in association with

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Beth Probert:                          

Now, Leah Szumita, I’d like to bring you in on this conversation because we heard eight new medicines right now. That’s huge. And as Dr. Daver said, those are the results of clinical trials. And, recently, I heard that only about 5 to 8 percent of adult cancer patients are participating nationwide, in the United States, in clinical trials. That seems like such a small number. And we depend on these patients to participate in these clinical trials to come out with these eight new meds.

There’s definitely a gap. And I’d like to hear your feedback about just that. And then, if you can go into—I’m going to ask you a few more questions about how people get involved in clinical trials. So, take us through that.

Leah Szumita:                          

Great, I will. So, I have to echo Dr. Daver’s sentiments about the importance of the genomic testing as well. And really, the new breakthrough in AML therapy is just a testament to the ongoing research. As he said, the research has been happening for 15 or 20 years. And we’re finally seeing the fruits of the labor. So, it’s encouraging. And that 5 to 8 percent is low, but there’s room for improvement. And I think many different organizations have identified barriers to why these enrollment rates are so low. I will say that, of all of the clinical trials, somewhere between two and ten percent of clinical trials have to close because of low accrual rate.

So, there is just serious work to be done. I think, you can look at barriers in two different ways. There are patient barriers. There’s just a lack of awareness that clinical trials exist for all stages of diseases. So, many people believe that a clinical trial is only for those who have exhausted all other treatment options. And so, that’s actually not true. There are trials for every stage of disease. Previously untreated, newly diagnosed, relapse refractory, maintenance and remission. There are other barriers that people are afraid to be a guinea pig.

And so, I think, as healthcare providers, that’s our job to really educate that clinical trials are very controlled, closely monitored situations, provide education on the different phases and what those mean. There are very complex and stringent inclusion/exclusion criteria to clinical trials, which, in one way, can make it very difficult to understand, if you’re even eligible for a trial.

And so, that’s why clinical trial nurse navigators, such as myself, can really help patients and caregivers sort through that information. And then, sometimes, physicians aren’t aware of all of the trials that are out there either. And that is not to slight practitioners, but, again, it’s just an overwhelming amount of information. It takes time to stay on top of all of this research. It takes time to go through all of this research and all of the different protocols.

And so, it’s really important for patients and caregivers to have an advocate to try to identify what clinical trial is right for them.

Beth Probert:                         

Can you talk about what questions someone can ask their doctor, in regard to clinical trials?

What are those important questions?

Leah Szumita:                          

Absolutely. So, there are so many of them. And one of the things that my group of nurses and myself do is really provide people with education about the basics of clinical trials and then, the language and the questions they can use, when they go back to their provider. And then, also, when they go to make that connection with the clinical trial group. So, the list is long. I would say first and foremost, asking what the risks and benefits are. Many times, in a clinical trial, there are different requirements about how often someone might come to and from the site, what the finances might be related to that.

Also, a lot of studies or drugs used in studies have been used in other studies. So, asking if there are any early results or any results from prior studies using those medications is important.

And asking about how this may affect quality of life, all of those different kinds of questions. There’s a very long list. We do have a fabulous clinical trials booklet that patients and caregivers can obtain that have lists of questions. And we always encourage people to read through that material as well. But knowledge is power. So, the more knowledge and research someone does, and bringing someone with them to these appointments to really take notes because it can be so difficult to absorb all of this information, would be some of my recommendations.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

How Likely Is It for a Patient's Myelofibrosis or MDS to Transform Into AML?

What percentage of people with MDS or an MPN transform into AML? Our expert panel explains the signs to look for and what tests are done for patient risk assessment.

Published:

What Are the Side Effect Profiles for Modern AML Treatments?

What potential side effects can AML patients expect from powerful new therapies? Expert, Dr. Ross Levine explains.

Published:

How to Test for, Identify and Treat AML Subtypes

How many subtypes of AML are there? Are you getting the right testing done? AML expert Dr. Ross Levine joined us at ASH 2017 to discuss testing for subtypes and an individualized approach to treatment.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 21, 2019